|
|
Post by Tony Crispino on Dec 23, 2013 15:05:26 GMT -8
From the ASCO Wire: Science Magazine Names Cancer Immunotherapy as Scientific Breakthrough of the Year
This is not prostate cancer specific but an interesting post anyway. We already have Provenge. But we also have PROSTvac and Ipillamumab in trials. I'm sure more will follow. Key Points: - The journal Science has named cancer immunotherapy as its top Scientific Breakthrough of the Year.
- Although the full potential of cancer immunotherapy remains unclear, the editors of Science agreed that the approach of using the immune system to attack tumors marks a turning point in the treatment of cancer.
- The success of recent clinical studies of immunotherapies is encouraging pharmaceutical companies to develop antibodies, such as anti–PD-1.
Tony |
|
Jerry
Junior Member
Posts: 44 
|
Post by Jerry on Feb 19, 2014 17:52:49 GMT -8
Delivering a Triple-Knockout Punch to Prostate Cancer
—A novel cancer immunotherapy approach receives a $1 million Movember-Prostate Cancer Foundation Challenge Award: February 18, 2014 -- The journal Science, anointed advances in cancer immunotherapy as the 2013 Breakthrough of the Year –the “It” science story. Exciting advancements in approaches that enable a type of immune cell, called T-cells, to specifically target tumor cells and kill them, surely drove the editors at Science in their selection. And by early indications, 2014 could be another banner year in terms of moving cancer immunotherapy forward. A new Movember-PCF Challenge Award to a team of cancer immunologists at the City of Hope National Medical Center, will fund the development of an entirely unique and innovative combination immunotherapy approach. The strategy: Amp up a patient’s natural immune defenses to fight off prostate cancer by combining two stand-alone immunotherapies that target different aspects of the immune system that are comprised by the cancer...
...The combination immunotherapy to be developed under the Movember-PCF Challenge Award will, A) use RNA interference to limit the amount of a protein (STAT3) that both promotes cancer cell growth, and inhibits the immune system from killing off cancer cells; and B) engineer a prostate cancer patient’s own T-cells to recognize and kill cancer cells. This combination approach will involve two different novel drug candidates that in sum, deliver three separate blows to cancer cells.
Link to PCF Article on ImmunotherapyEncouraging and looks like it is comes in with some $$$. Sounds like they are hopeful that clincial trials can start in 2015. One of my complaints for years with Provenge is that it was never approved for hormone sensitive patients....I hope they can do some trials for hormone sensitive and earlier in the disease. And, I hope it doesn't get as controversial as Provenge was/is.
|
|
